• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $MYOK

    MyoKardia, Inc.

    Subscribe to $MYOK
    $MYOK
    Major Pharmaceuticals
    Health Care

    IPO Year: 2015

    Exchange: NASDAQ

    Recent Analyst Ratings for MyoKardia, Inc.

    DatePrice TargetRatingAnalyst
    See more ratings

    MyoKardia, Inc. FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for CAMZYOS issued to MYOKARDIA INC

    Submission status for MYOKARDIA INC's drug CAMZYOS (ORIG-1) with active ingredient MAVACAMTEN has changed to 'Approval' on 04/28/2022. Application Category: NDA, Application Number: 214998, Application Classification: Type 1 - New Molecular Entity

    4/29/22 9:42:47 AM ET
    $MYOK
    Major Pharmaceuticals
    Health Care